Ehave,
Inc.
To Acquire
Mdlink The
Largest Telemedicine
Platform in
The
CARICOM
Countries And
To
Launch
Mdlink Mental Therapy along with
Psychedelic Treatments To
Address Mental
Health
Ehave enters
lucrative Market Slated to Grow
from $34.28 billion in 2018
$185.66 billion by 2026
MIAMI, FL -- June
2, 2020 -- InvestorsHub Newsire -- Ehave, Inc., (OTC
Pink: EHVVF) (the "Company"), a provider of digital
therapeutics delivering evidence-based therapeutic interventions to
patients, announced today announced it has signed a
letter of intent to acquire 51% of MDLink a
Caribbean
Telemedicine provider, MDLink Limited ("MDLink"), a
company organized and existing
under the laws of Jamaica. Mdlink is licensed for all
CARICOM Countries which include Antigua and Barbuda,
Belize, Dominica, Grenada, Guyana,
Haiti, Jamaica, Montserrat, Saint Kitts, Nevis, Saint Lucia, Saint
Vincent, Rhe Grenadines, Suriname and Trinidad and Tobago. Mdlink
currently has over 10,000 patients. The terms of the agreement
require Ehave to develop a platform for MDLink Mental
Health Therapy.
MDLink is the
pioneer of Telemedicine and the only operational Telemedicine
platform in the region. Founder and CEO, Dr. Ché Bowen, launched
MDLink in 2017 and has since spearheaded the Telehealth movement
through the region. MDLink provides services
in Psychiatry, General Practice, Urgent
Care and Dermatology.
MDLink
was the first to
have a partnership with a regional telecommunications company-
Cable & Wireless/Flow. With more than 10,000+ registered
patients, MDLink is the first telemedicine provider to
launch a COVID-19 A.I. Chatbot in the region next month, "MD Lex."
Additionally, MDLink is a member of the
Psychiatric Association of Jamaica.
Millions of
patients around the world are already consulting with
physicians
online, and
Telemedicine has proven to be a safe, effective and more convenient
option to access healthcare. MDLink provides the best online
security for patients' health information using
HIPAA guidelines. MDLink will integrate Ehave's
dashboard and Ehave's licensed MylifeID into its Telemedicine platform to
have patients' medical records at
its
fingertips.
Ehave will be
implementing MDLink Mental help to take
advantage of the growing
medical tourism and
psychedelic retreats as Jamaica is ground
zero for psychedelic
activity.
Today, more than 300 million people suffer from depression
worldwide, with about 100 million of whom do not respond to
available treatments. Psychedelic medicine offers the potential to
revolutionize the mental health industry and is witnessing
staggering growth.
Ehave will be positioned
to meet the needs of the over 90+ psychedelic clinics and 30
million underground psychedelic users. The company's platform will
allow mental health specialists to provide psychedelic aftercare
along with addiction, and holistic wellness services and
programs
though use of Ketamine, Psilocybin, Ayahuasca and other available
psychedelic
treatment.
The global
telemedicine market size is expected to grow from $34.28 billion in
2018 $185.66 billion by 2026, according to a recent report by
Fortune Business Insights. Research firm Global Market Insights,
Inc. predicts the following trends in the Telemedicine
market:
Increasing cases
of COVID-19 infection across the globe and growing influence of
social distancing will drive the market.
Increasing need
to lower the overall healthcare cost and technological advancements
will be conducive to the market growth.
Tele-monitoring
services will be increasingly adopted to lower the burden on
medical fraternity.
Minimizing the
spread of COVID-19 infection among healthcare staff will lead to
growth in the telehospital segment growth.
Neurology segment
will witness significant growth across the forecast
timeframe.
Growing
importance of social distancing and self-quarantine will lead to
increase in the number of virtual calls.
Some of the
prominent players operating in the e-health market are Allscripts
Healthcare Solutions Inc., AMD Global
Telemedicine, Telus Corporation, Teladoc
Health, Medtronic PLC, Anthem, Inc., CVS Health Corporation,
Benefytt Technologies, and Humana Inc.
In November of
2010 Prof. Victor S. Dorodny, MD (Ehave's Advisory Board
member) realigned his then
17-year-old health care policy, economics and information
technology consulting company to refocus on health information
technology (HIT) and Telehealth. Prof. Dorodny's expertise
and enthusiasm foster strategic partnerships between HIT
manufacturers, medical service providers, consumers, and
payors.
"The
current Global health care system needs to
expand the use of Health Information Technologies (HIT) and
Telemedicine. The system emerged in the wake of latest health care
legislation will crash without it," says Dr. Victor Dorodny.
"Adding millions of health care consumers, while mandating extended
coverage, combined with increased demand for health care from the
aging baby boomers is straining the system at the seams.
Telemedicine seems to be our best viable alternative to provide
health care for the ever growing needs of the consumer, especially
the chronically ill and aging. I have no doubt that health care
delivery in the World will change dramatically in
the next ten years through the adoption of telemedicine. We are in
the convergent space defined by medicine, information, and
technology, and plan to work hard on integrating them for the
benefit of the health care system. Ehave, by acquiring the
controlling package of MDLink, becomes a real player in the field,
with array of offerings that are complementary
for/to provision
of Telemed/Telehealth services".
MDLink Founder
and CEO, Dr. Ché Bowen said, "We are pleased to partner
with Ehave as we are confident in the work of their superior team
of experts in both the Digital Health and Mental Health sectors.
Dr. Bowen strongly believes that mental health is a very prominent
yet neglected patient population and as such he is looking forward
to helping more patients via MDLink."
Ben Kaplan, CEO
of Ehave, Inc. said, "By adding the MDLink network and expertise,
Ehave can further expand into Clinical trials of
Psychedelics and enhance our mental and
behavioral health programs, an exciting and important
endeavor that will positively impact patients, their families, and
the treatment teams providing their care, while advancing clinical
outcomes and reducing overall costs." he said.
Download our App
on our Website or your Device Store
https://themdlink.com/home
https://apps.apple.com/ag/app/mdlink-health/id1441006209
https://play.google.com/store/apps/details?id=com.mdlinkhealth
About Ehave,
Inc.
Ehave,
Inc. is a provider of digital therapeutics delivering
evidence-based therapeutic interventions to patients. Our primary
focus is on improving the standard care in therapeutics to prevent
or treat brain disorders or diseases through the use of digital
therapeutics, psychedelics, independently or together, with
medications, devices, and other therapies to optimize patient care
and health outcomes meeting privacy and HIPAA
&
GDPR
Compliant. Our main product is the Ehave Dashboard which is a
mental health informatics platform that allows clinicians to make
objective and intelligent decisions through data insight using
Blockchain technology. The Ehave dashboard offers Offline Encrypted
Digital Records Empowering Healthcare providers and patients and
it's a powerful machine learning and artificial intelligence
platform using artificial intelligence to extract deep insights
from audio, video and text to improve research with a growing set
of advanced tools and applications developed by Ehave and its
leading partners. This empowers patients, healthcare providers, and
payers to address a wide range of conditions through high quality,
safe, and effective data-driven involvement with intelligent and
accessible tools.
Forward-Looking
Statement Disclaimer
This press
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward-looking statements are based on certain assumptions
and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company's control, and
cannot be predicted or quantified and consequently, actual results
may differ materially from those expressed or implied by such
forward-looking statements: (i) the initiation, timing, progress
and results of the Company's research, manufacturing and other
development efforts; (ii) the Company's ability to advance its
products to successfully complete development and
commercialization; (iii) the manufacturing, development,
commercialization, and market acceptance of the Company's products;
(iv) the lack of sufficient funding to finance the product
development and business operations; (v) competitive companies and
technologies within the Company's industry and introduction of
competing products; (vi) the Company's ability to establish and
maintain corporate collaborations; (vii) loss of key management
personnel; (viii) the scope of protection the Company is able to
establish and maintain for intellectual property rights covering
its products and its ability to operate its business
without
infringing the intellectual property rights of others; (ix)
potential failure to comply with applicable health information
privacy and security laws and other state and federal privacy and
security laws; and (x) the difficulty of predicting actions of the
USA FDA and its regulations. All forward-looking statements
included in this press release are made only as of the date of this
press release. The Company assumes no obligation to update any
written or oral forward-looking statement unless required by law.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
contained under the heading "Risk Factors" in Ehave, Inc.'s
Registration Statement on Form F-1 filed with the Securities and
Exchange Commission (SEC) on September 24, 2015, as amended, which
is available on the SEC's website, http://www.sec.gov.
Media and
Investors
Relations, please contact:
Gabe
Rodriguez
Phone: (623)
261-9046
Email:
erelationsgroup@gmail.com